NIKKEI 225
27,327.11 -106.29 (-0.39%) HANG SENG
21,842.33 -227.40 (-1.03%) CRUDE OIL
78.71 +0.81 (+1.04%) GOLD FUTURES
1,945.50 +6.30 (+0.32%) DOW
33,859.21 +142.12 (+0.42%) BTC-GBP
18,798.93 -88.84 (-0.47%)
Verastem, Inc. (0LOV.L)
| Previous close | 0.6796 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 507,369 |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4110 |
| Earnings date | 27 Mar 2023 - 31 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the plac
- Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON, January 24, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC). The Company is also providing a
